Relationship between polymorphism of class II transactivator gene promoters and chronic hepatitis B

World Journal of Gastroenterology

Volumn 11, Issue 6, 2005, Pages 854-857

  Zhao, Ying Ren ^a   Gong, Ling ^a   He, Ying Li ^a   Liu, Fang ^a   Lu, Chang ^a  

^a THE FIRST AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

Author keywords

Class II transactivator gene promoter; Hepatitis B

Indexed keywords

GENOMIC DNA; TRANSACTIVATOR PROTEIN;

ACUTE DISEASE; ADULT; ARTICLE; CHRONIC HEPATITIS; CONTROLLED STUDY; DNA SEQUENCE; FEMALE; GENETIC CONSERVATION; GENETIC POLYMORPHISM; HEPATITIS B; HUMAN; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PROMOTER REGION; PROTEIN DOMAIN; PROTEIN TRANSPORT; SEQUENCE ANALYSIS; SINGLE STRAND CONFORMATION POLYMORPHISM;

EID: 14544296585     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v11.i6.854     Document Type: Article

References (42)

1. Steimle V, Otten LA, Zufferey M, Mach B. Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome). Cell 1993; 75: 135-146
2. Ting JP, Trowsdale J. Genetic control of MHC class II expression. Cell 2002; 109(Suppl): S21-33
3. van den Elsen PJ, Holling TM, Kuipers HF, van der Stoep N. Transcriptional regulation of antigen presentation. Curr Opin Immunol 2004; 16: 67-75
4. Schnappauf F, Hake SB, Camacho Carvajal MM, Bontron S, Lisowska-Grospierre B, Steimle V. N-terminal destruction signals lead to rapid degradation of the major histocompatibility complex class II transactivator CIITA. Eur J Immunol 2003; 33: 2337-2347
5. Nagarajan UM, Bushey A, Boss JM. Modulation of gene expression by the MHC class II transactivator. J Immunol 2002; 169: 5078-5088
6. Otten LA, Steimle V, Bontron S, Mach B. Quantitative control of MHC class II expression by the transactivator CIITA. Eur J Immunol 1998; 28: 473-478
7. Muhlethaler-Mottet A, Otten LA, Steimle V, Mach B. Expression of MHC class II molecules in different cellular and functional compartments is controlled by differential usage of multiple promoters of the transactivator CIITA. EMBO J 1997; 16: 2851-2860
8. Lennon AM, Ottone C, Rigaud G, Deaven LL, Longmire J, Fellous M, Bono R, Alcaide-Loridan C. Isolation of a B-cell-specific promoter for the human class II transactivator. Immunogenetics 1997; 45: 266-273
9. Wong AW, Ghosh N, McKinnon KP, Reed W, Piskurich JF, Wright KL, Ting JP. Regulation and specificity of MHC2TA promoter usage in human primary T lymphocytes and cell line. J Immunol 2002; 169: 3112-3119
10. Pai RK, Askew D, Boom WH, Harding CV. Regulation of class II MHC expression in APCs: Roles of types I, III, and IV class II transactivator. J Immunol 2002; 169: 1326-1333
11. Abendroth A, Slobedman B, Lee E, Mellins E, Wallace M, Arvin AM. Modulation of major histocompatibility class II protein expression by varicella-zoster virus. J Virol 2000; 74: 1900-1907
12. Kanazawa S, Okamoto T, Peterlin BM. Tat competes with CIITA for the binding to P-TEFb and blocks the expression of MHC Class II genes in HIV infection. Immunity 2000; 12: 61-70
13. Accolla RS, Mazza S, De Lerma Barbaro A, De Maria A, Tosi G. The HLA class II transcriptional activator blocks the function of HIV-1 Tat and inhibits viral replication. Eur J Immunol 2002; 32 2783-2791
14. Yazawa T, Ito T, Kamma H, Suzuki T, Okudela K, Hayashi H, Horiguchi H, Ogata T, Mitsui H, Ikeda M, Kitamura H. Complicated mechanisms of class II transactivator transcription deficiency in small cell lung cancer and neuroblastoma. Am J Pathol 2002; 161: 291-300
15. Sartoris S, Brendolan A, Degola A, Testi MG, Chignola R, Scarpa A, Scardoni M, Contreas G, Pinelli L, Lunardi C, Beri R, Pera C, Ferrara GB, Riviera AP, Tridente G, Andrighetto G. Analysis of CIITA encoding AIR-1 gene promoters in insulin-dependent diabetes mellitus and rheumatoid arthritis patients from the Northeast of Italy: Absence of sequence variability. Hum Immunol 2000; 61: 599-604
16. Rasmussen HB, Kelly MA, Clausen J. Genetic susceptibility to multiple sclerosis: Detection of polymorphic nucleotides and an intron in the 3′ untranslated region of the major histocompatibility complex class II transactivator gene. Hum Immunol 2001; 62: 371-377
17. Iino S. Natural history of hepatitis B and C virus infections. Oncology 2002; 62(Suppl 1): 18-23
18. Wang FS. Current status and prospects of studies on human genetic alleles associated with hepatitis B virus infection. World J Gastroenterol 2003; 9: 641-644
19. McNicholl JM, Cuenco KT. Host genes and infectious diseases. HIV, other pathogens, and a public health perspective. Am J Prev Med 1999; 16: 141-154
20. Dean M, Carrington M, O'Brien SJ. Balanced polymorphism selected by genetic versus infectious human disease. Annu Rev Genomics Hum Genet 2002; 3: 263-292
21. Hill AV. The immunogenetics of human infectious diseases. Annu Rev Immunol 1998; 16: 593-617
22. Kwiatkowski D. Genetic dissection of the molecular pathogenesis of severe infection. Intensive Care Med 2000; 26 Suppl 1): S89-97
23. Thursz M. Genetic susceptibility in chronic viral hepatitis. Antiviral Res 2001; 52: 113-116
24. Branch society of infectious disease and parasitology and branch society of hepatology of Chinese medical association. National preventiont and treatment profiles of viral hepatitis (2000). Zhonghua Chuanranbing Zazhi 2001; 19: 56-62
25. Zhang S, Chen Y. HBV serum marker detection and relative factor analysis of 2925 new students. Public Health 1998; 112: 257-259
26. Cheng YQ, Lin JS, Huang LH, Tian DY, Yiong P. The association of HLA-DRB1 allele polymorphism with the genetic susceptibility to liver cirrhosis due to hepatitis B virus. Zhonghua Yixue Yixhuanxue Zazhi 2003; 20: 247-249
27. Hohler T, Gerken G, Notghi A, Lubjuhn R, Taheri H, Protzer U, Lohr HF, Schneider PM, Meyer zum Buschenfelde KH, Rittner C. HLA-DRB1*1301 and *1302 protect against chronic hepatitis B. J Hepatol 1997; 26: 503-507
28. Thio CL, Carrington M, Marti D, O'Brien SJ, Vlahov D, Nelson KE, Astemborski J, Thomas DL. Class II HLA alleles and hepatitis B virus persistence in African Americans. J Infect Dis 1999; 179 1004-1006
29. Karan MA, Tascioglu NE, Ozturk AO, Palanduz S, Carin M. The role of HLA antigens in chronic hepatitis B virus infection. J Pak Med Assoc 2002; 52: 253-256
30. Kim YJ, Lee HS, Yoon JH, Kim CY, Park MH, Kim LH, Park BL, Shin HD. Association of TNF-alpha promoter polymorphisms with the clearance of hepatitis B virus infection. Hum Mol Genet 2003; 12 2541-2546
31. Park BL, Lee HS, Kim YJ, Kim JY, Jung JH, Kim LH, Shin HD. Association between interleukin 6 promoter variants and chronic hepatitis B progression. Exp Mol Med 2003; 35: 76-82
32. Ben-Ari Z, Mor E, Papo O, Kfir B, Sulkes J, Tambur AR, Tur-Kaspa R, Klein T. Cytokine gene polymorphisms in patients infected with hepatitis B virus. Am J Gastroenterol 2003; 98: 144-150
33. Miyazoe S, Hamasaki K, Nakata K, Kajiya Y, Kitajima K, Nakao K, Daikoku M, Yatsuhashi H, Koga M, Yano M, Eguchi K. Influence of interleukin-10 gene promoter polymorphisms on disease progression in patients chronically infected with hepatitis B virus. Am J Gastroenterol 2002; 97: 2086-2092
34. Song le H, Binh VQ, Duy DN, Juliger S, Bock TC, Luty AJ, Kremsner PG, Kun JF. Mannose-binding lectin gene polymorphisms and hepatitis B virus infection in Vietnamese patients. Mutat Res 2003; 522: 119-125
35. Bellamy R, Ruwende C, Corrah T, McAdam KP, Thursz M, Whittle HC, Hill AV. Tuberculosis and chronic hepatitis B virus infection in Africans and variation in the vitamin D receptor gene. J Infect Dis 1999; 179: 721-724
36. Accolla RS, Jotterand-Bellomo M, Scarpellino L, Maffei A, Carra G, Guardiola J. AIr-1, a newly found locus on mouse chromosome 16 encoding a trans-acting activator factor for MHC class II gene expression. J Exp Med 1986; 164: 369-374
37. Martin BK, Chin KC, Olsen JC, Skinner CA, Dey A, Ozato K, Ting JP. Induction of MHC class I expression by the MHC class II transactivator CIITA. Immunity 1997; 6: 591-600
38. Kadota Y, Okumura M, Miyoshi S, Kitagawa-Sakakida S, Inoue M, Shiono H, Maeda Y, Kinoshita T, Shirakura R, Matsuda H. Altered T cell development in human thymoma is related to impairment of MHC class II transactivator expression induced by interferon-gamma (IFN-gamma). Clin Exp Immunol 2000; 121: 59-68
39. Sisk TJ, Gourley T, Roys S, Chang CH. MHC class II transactivator inhibits IL-4 gene transcription by competing with NF-AT to bind the coactivator CREB binding protein (CBP)/p300. J Immunol 2000; 165: 2511-2517
40. Quan V, Towey M, Sacks S, Kelly AP. Absence of MHC class II gene expression in a patient with a single amino acid substitution in the class II transactivator protein CIITA. Immunogenetics 1999; 49: 957-963
41. Marten A, Ziske C, Schottker B, Weineck S, Renoth S, Buttgereit P, Schakowski F, Konig S, von Rucker A, Allera A, Schroers R, Sauerbruch T, Wittig B, Schmidt-Wolf IG. Transfection of dendritic cells (DCs) with the CIITA gene: Increase in immunostimulatory activity of DCs. Cancer Gene Ther 2001; 8: 211-219
42. Sartoris S, Valle MT, Barbaro AL, Tosi G, Cestari T, D'Agostino A, Megiovanni AM, Manca F, Accolla RS. HLA Class II expression in uninducible hepatocarcinoma cells after transfection of AIR-1 gene product CIITA: Acquisition of antigen processing and presentation capacity. J Immunol 1998; 161: 814-820